Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Exploring Targeted Protein Degradation as a New Strategy to Tackle Antimicrobial Resistance

Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria.

28 Jan 2026

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud Biosciences, an innovator in organoid development and complex 3D biology, today announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.

27 Jan 2026

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

27 Jan 2026

Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation

A multidisciplinary USC research team has identified new compounds that may target a key driver of brain inflammation linked to Alzheimer's disease. Their research just published in the Nature publication npj Drug Discovery.

24 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening

Sino Biological, Inc. is proud to announce the launch of its innovative SwiftFluo TR-FRET Kinase Assay Kits, a ready-to-use, high-performance solution designed to accelerate kinase activity detection and high-throughput kinase inhibitor screening.

From Sino Biological Inc. 21 Jan 2026

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Cell and Gene Therapy 2026. Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute) will lead the inaugural two-day event taking place at Hinxton Hall in Cambridge, UK from 9-10 March.

20 Jan 2026

Accelerating kinase drug discovery with validated kinase activity assay kits

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

From Eurofins Discovery 20 Jan 2026

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners.

From Concept Life Sciences 19 Jan 2026

Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University improves upon traditional methods of targeting bladder cancer cells with messenger RNA (mRNA) therapies.

16 Jan 2026

AI identifies promising CDK9 inhibitors for cancer treatment

A new and important discovery comes from the field of oncological research thanks to the joint work of researchers from the Sbarro Institute in Philadelphia, the National Cancer Institute – Pascale Foundation, and the University of Pisa.

16 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Axol Bioscience raises $2.8 M to advance US expansion and product development

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding.

13 Jan 2026

Magnetic torque boosts cardiac organoid maturation, mimicking heart development

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the shortcomings of existing experimental models.

13 Jan 2026

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

12 Jan 2026

New publication describes the chemical journey of non-hormonal male birth control pill

A newly published manuscript authored by Dr. Gunda Georg, YourChoice Therapeutics and Columbia University Medical Center describes the chemical journey of YCT-529, a non-hormonal male birth control pill, and the promising molecular science behind it.

12 Jan 2026

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced today that it has implemented CDD Vault®, the secure, cloud-based research informatics platform from Collaborative Drug Discovery (CDD).

From Collaborative Drug Discovery, Inc. 10 Jan 2026

Drug Discovery News and Research

Further Reading

Exploring Targeted Protein Degradation as a New Strategy to Tackle Antimicrobial Resistance

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

Accelerating kinase drug discovery with validated kinase activity assay kits

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies

AI identifies promising CDK9 inhibitors for cancer treatment

New chemistry revives neurokinin-1 receptor as depression treatment target

Axol Bioscience raises $2.8 M to advance US expansion and product development

Magnetic torque boosts cardiac organoid maturation, mimicking heart development

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

New publication describes the chemical journey of non-hormonal male birth control pill

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

APOE gene: A major driver in Alzheimer's disease

UC Davis team creates new class of serotonin-effecting drugs

Newly discovered molecules accelerate the removal of immune-modulating enzyme

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®